Page 5 - Phasei Program News Today

Gastrointestinal oncology experts discuss current strategies and novel developments in gastrointestinal cancers, the role of intestinal dysbiosis and gastrointestinal carcinogenesis, germline genetic features in appendiceal cancer, and the need for anticipatory, multidisciplinary guidance in clinical practice.

Antoinette R. Tan, MD, MHSc, discusses the promise of oral selective estrogen receptor degraders as they continue to be developed for the treatment of patients with ER-positive, HER2-negative breast cancer, factors that inform treatment decisions following disease progression on a CDK4/6 inhibitor, and the growing role of antibody-drug conjugates across the breast cancer spectrum.

The FDA has granted an orphan drug designation to PYX-201 for the treatment of patients with pancreatic cancer.

Dr. Vivek Subbiah to Serve as Chief, Early-Phase Drug Development Across SCRI's Research Network Sarah Cannon Research Institute (SCRI), one of the world's leading oncology research organizations

VT3989, a first-in-class YAP/TEAD inhibitor, showcased durable antitumor activity and tolerability in patients with malignant mesothelioma and other solid tumors harboring NF2 mutations, according to data from a phase 1 trial presented at the 2023 AACR Annual Meeting.

16.03.2023 - Milestone marks transition of Pyxis Oncology to a clinical-stage company Preliminary data anticipated in early 2024 CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) - Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on ... Seite 1

STO is pleased to announce the addition of Drs. Sean Khozin, Ke Liu, Mace L. Rothenberg, and Lillian L. Siu to its Board of Directors.

Patient-Reported Outcomes with Mirvetuximab Versus Chemotherapy in FORWARD I Study Reinforces Differentiated Tolerability Profile ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field

Press release content from Business Wire. The AP news staff was not involved in its creation.

CARLSBAD, Calif., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing...